Navigation Links
Lilly Reports Fourth-Quarter and Full-Year 2009 Results
Date:1/28/2010

an asset impairment and restructuring charge of $37.9 million (pretax), or $0.02 (after-tax). This charge is primarily related to severance costs from previously announced strategic actions. In addition, the fourth quarter and full-year 2009 financial statements have been adjusted to eliminate a charge of $90.0 million (pretax), or $0.05 per share (after-tax), for acquired in-process research and development associated with the licensing agreement with Incyte. (b) The 2009 full-year financial statement has also been adjusted to eliminate an additional special pretax charge of $230.0 million, or $0.13 per share (after-tax), related with several states' litigation claims involving Zyprexa. In addition, the full-year 2009 financial statement has been adjusted to eliminate an asset impairment and restructuring charge of $424.8 million (pretax), or $0.26 (after-tax) primarily related to severance costs from previously announced strategic actions. (c) The 2008 fourth-quarter and full-year financial statements have been adjusted to eliminate a charge of $4.730 billion (pre-tax), or $4.46 per share (after tax), for acquired in-process research and development as well as ImClone operating results subsequent to the acquisition, including $35.6 million of Erbitux sales, incremental interest costs and amortization of the intangible asset associated with Erbitux; a charge of $80.0 million (pre-tax), or $0.05 per share (after tax), for asset impairments, restructuring and other special charges primarily related to severance costs from previously announced strategic actions; and a tax benefit of $136.9 million, or $0.13 per share, based upon a determination that a portion of the EDPA settlement is tax deductible.
'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Investor-Edge has initiated coverage ... IMMU ), Aeterna Zentaris Inc. (NASDAQ: AEZS ... Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences ... can be accessed at: http://investor-edge.com/register . ... at 4,505.85, down 0.14%, the Dow Jones Industrial Average ...
(Date:9/30/2014)... , Sept. 30, 2014 It is evident from ... market is not performing upto expectations due to the lack ... asscoaited with the intake of omega-3 fatty acids. Among omega-3 ... the fish oil, attributed to the large vegetarian population in ... omega-3 polyunsaturated fatty acid (PUFAs) ingredients is in growth stage ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
Breaking Medicine Technology:Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5
... 2007 - Corgenix Medical,Corporation (OTC BB: CONX) ... data demonstrating a significant correlation,between serum levels ... disease. The data was presented at,the XXIst ... and,Hemostasis (ISTH) in Geneva, Switzerland., Data released ...
... of rHuPH20 with Humira Estimated to ... from 64% to 100%,-, SAN DIEGO, ... Inc. , a biopharmaceutical company developing ... that,final results of the Enhanze(TM) Technology ...
Cached Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:9/30/2014)... Sheridan Healthcare, Inc. , ... today announced that Adam Blomberg, MD, the national ... present at the Society for Healthcare Strategy & ... . The conference will be held October 12-15 ... a four-day conference that draws in more than ...
(Date:9/30/2014)... TN (PRWEB) September 30, 2014 ... of people throughout the United States and worldwide. ... Parkinson’s Disease are diagnosed each year, adding to ... with the disease. Approximately 400,000 people in the ... million worldwide. Add to these statistics the 2.4 ...
(Date:9/30/2014)... 2014 (HealthDay News) -- In books and movies, plots involving ... Now, new research suggests that the stereotype may be ... at data on more than 12,000 people from Finland. ... Turku, Finland, found that women typically preferred men who were ... throughout their lives. On the other hand, men tended ...
(Date:9/30/2014)... Bank, New Jersey (PRWEB) September 30, 2014 ... largest not-for-profit visiting nurse association—is pleased to announce that ... was honored with a NJBIZ “40 Under 40” ... of New Jersey’s most accomplished young businessmen and women ... who share a commitment to business growth, professional excellence ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 ... company focused on the peripheral nerve repair market, announced ... during the American Society for Surgery of the ... week in Boston. , The ASSH ... the Utilization of Processed Nerve Allografts for Large Gap ...
Breaking Medicine News(10 mins):Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5
... estimated 2 million women in the United States are ... the chronic and abnormal swelling of the arm, chest, ... treatment. While physicians will recommend proven techniques to manage ... that patients often won,t follow the recommendations, or they ...
... times more apt to develop the lung artery disorder, study ... four times more likely to develop a debilitating and potentially ... shows. , Pulmonary hypertension is caused by high blood pressure ... who suffer from the condition can become tired, dizzy and ...
... the question, do barriers to health care for ... tuberculosis? The study, published in the November 15, ... and now available online, suggests that undocumented immigrants ... than documented immigrants or U.S.-born patients, resulting in ...
... CEO John G. Schulte with Chairman ... Emile J. Geisenheimer., ... lawsuit on behalf of those who purchased Spectranetics Company,stock (Nasdaq: ... officer violated U.S. securities laws through illegal,marketing practices and false statements ...
... of their Regional PPO Network Area Pay ... ... Life Insurance Company,of America (Guardian), a leading provider of employee and ... Extended Access "travel network" for its health plan members.,Members utilizing health ...
... Pittsburgh-based Foundation,Radiology Group (FRG) signed a multi-year ... exclusive provider of diagnostic,imaging services effective December 31, ... in Coudersport Pennsylvania,and services multiple counties in north ... provides a wide range of primary and,secondary health ...
Cached Medicine News:Health News:MU study identifies patient strategies for managing symptoms of lymphedema 2Health News:MU study identifies patient strategies for managing symptoms of lymphedema 3Health News:Women at Higher Risk for Pulmonary Hypertension 2Health News:Health-care barriers for undocumented immigrants: Raising tuberculosis risk? 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 3Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 4Health News:Guardian Provides National Access to In-Network Medical Benefits 2Health News:Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: